Literature DB >> 26315520

Screening for Viral Hepatitis and Hepatocellular Cancer.

Andrew M Cameron1.   

Abstract

Accurate tests for at-risk populations are available for hepatitis B virus, hepatitis C virus (HCV), and hepatocellular carcinoma (HCC). Effective treatments for all three diseases exist if diagnosed early. New antivirals are making a significant impact on HCV. Liver transplant is curative for early HCC and is prioritized by the United Network for Organ Sharing in the United States. Screening and surveillance for deadly disease only makes sense if there are identifiable populations at risk for the condition, there are sensitive and specific low-cost tests available for the condition, and there are effective treatments for the condition.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Screening; Surveillance

Mesh:

Year:  2015        PMID: 26315520     DOI: 10.1016/j.suc.2015.05.005

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Hepatocyte selection medium-enriched hepatocellular carcinoma cells are positive for α-fetoprotein and CD44.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2017-05-24       Impact factor: 2.967

2.  Comparison of DWIBS/T2 image fusion and PET/CT for the diagnosis of cancer in the abdominal cavity.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yoshitaka Uchida; Katsuhiro Uchiyama; Satomi Tanaka; Takafumi Sunaoshi; Daisuke Kano; Eriko Sugiyama; Misaki Shite; Ryouta Haga; Yoshiya Fukamizu; Toshiyuki Fujita; Satoshi Kagayama; Rumiko Hasegawa; Yoshinori Shirai; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Exp Ther Med       Date:  2017-08-22       Impact factor: 2.447

3.  2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2016-12-16       Impact factor: 2.967

4.  Oct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

Review 5.  Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.

Authors:  Misu Lee; Haeyong Ko; Mijin Yun
Journal:  Yonsei Med J       Date:  2018-12       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.